Grand Theravac Life Sciences (nanjing) Co., Ltd.
Clinical trials sponsored by Grand Theravac Life Sciences (nanjing) Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New shot aims to silence hepatitis b virus in Long-Term patients Results expected Apr 2027 (estimated)
- New injection aims to tame chronic hepatitis b Results expected May 2027 (estimated)
-
New injection aims to tame chronic hepatitis b
Disease control Not yet recruitingThis early-stage trial tests an injection called TVAX-028 in adults with chronic hepatitis B. The study checks if the drug is safe and how the body processes it. Participants receive either TVAX-028 with an adjuvant or the adjuvant alone, at different dose levels. The goal is to …
Phase 1 • Sponsor: Grand Theravac Life Sciences (Nanjing) Co., Ltd. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New shot aims to silence hepatitis b virus in Long-Term patients
Disease control Not yet recruitingThis Phase 3 trial tests an injection called TVAX-008 for people with chronic hepatitis B. About 630 adults who have been on antiviral therapy for at least 6 months will receive either TVAX-008, a placebo, or an active comparator. The goal is to see if the treatment can clear hep…
Phase 3 • Sponsor: Grand Theravac Life Sciences (Nanjing) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC